Compare REGN & MAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | REGN | MAR |
|---|---|---|
| Founded | 1988 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.4B | 87.4B |
| IPO Year | 1995 | 2005 |
| Metric | REGN | MAR |
|---|---|---|
| Price | $781.39 | $328.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 16 |
| Target Price | ★ $819.54 | $345.25 |
| AVG Volume (30 Days) | 617.3K | ★ 1.8M |
| Earning Date | 04-16-2026 | 05-12-2026 |
| Dividend Yield | 0.49% | ★ 0.83% |
| EPS Growth | 8.19 | ★ 14.17 |
| EPS | ★ 41.48 | 9.51 |
| Revenue | $5,872,227,000.00 | ★ $26,186,000,000.00 |
| Revenue This Year | $11.69 | $7.18 |
| Revenue Next Year | $10.06 | $5.26 |
| P/E Ratio | ★ $18.31 | $34.01 |
| Revenue Growth | ★ 20.82 | 4.33 |
| 52 Week Low | $476.49 | $205.40 |
| 52 Week High | $821.11 | $370.00 |
| Indicator | REGN | MAR |
|---|---|---|
| Relative Strength Index (RSI) | 52.19 | 44.75 |
| Support Level | $740.39 | $309.94 |
| Resistance Level | $786.67 | $331.09 |
| Average True Range (ATR) | 21.05 | 8.86 |
| MACD | -2.04 | -3.48 |
| Stochastic Oscillator | 68.99 | 33.28 |
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Marriott operates 1.8 million rooms across roughly 30 brands. At the end of 2024, luxury represented roughly 10% of total rooms, premium was 43%, select service was 45%, midscale was 1%, and other was 1%. Marriott, Courtyard, and Sheraton are the largest brands, while Autograph, Tribute, Moxy, Aloft, and Element are newer lifestyle brands. Managed and franchised represented 98% of total rooms as of Dec. 31, 2024. North America makes up 62% of total rooms. Managed, franchise, and incentive fees represent the vast majority of revenue and profitability for the company.